Top 50 Health Care Startup Investors in Sweden in April 2025

ALMI Invest is a venture capital company which invests in Swedish companies with exciting, scalable business models and motivated entrepreneurs. ALMI Invest consists of eight regionally based venture capital funds, all with local offices and experienced local investment managers. We manage a total of SEK 1 billion. Unlike most venture capitalists,we can invest in a wide range of businesses. A strong team of entrepreneurs, a scalable business model and an initial revenue stream are more important than the line of business when we invest.Our first, initial investment would typically be SEK 2-4 million. During the lifetime of an investment, sums of up to SEK 10 million can be ventured. We always syndicate with an investment partner (another venture capitalist or angel investor) from Sweden or otherwise which means that we can take a maximum of 50 percent of an investment round.ALMI Invest was founded in 2009 by ALMI Fretagspartner together with regional investors. Half of our capital comes from European Union structural funds, which accounts for an investment of SEK 500 million. The other 50 per cent comes from regional investors and ALMI Fretagspartner.

Whether you are an investor or entrepreneur, partner with Sciety to achieve impactful returns and elevate your life science business in the Nordics.

We are a leading tech investor & venture builder in the Nordics. Taking deep tech from lab to market.WELCOMEINVESTMENTS

Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.

Luminar Ventures is a venture capital fund that prefers to make early-stage investments in technology companies. They engage with their portfolio companies and are actively helping with strategic, growth, team and organizational, and operational support, and together setting the foundation for future expansion.Luminar's core investment focusis on scalable digital seed-stage companies from the Nordics, founded by highly motivated and talented entrepreneurs with a vision to disrupt or transform major industries. The firm aims to provide experienced seed-stage financing and active operational support to Sweden based early-stage technology companies that are looking to disrupt or transform major industries with digital technologies and innovations.

Add Health Media is a company that specializes in creating marketing materials for health companies.

Sophia Bendz - Partner @ Cherry Ventures

Partnerinvest Norr is a private equity firm specialized in software, security, and biometrics sectors. Partnerinvest Övre Norrland AB is a venture capital firms that seeks to invest in limited companies which have are in the expansion phase.

SEB Venture Capital is a Fintech investor that helps entrepreneurs and innovators launch and grow profitable businesses. They primarily serve as a strategic corporate venture focused on Fintech investments, with the option of partnering with SEB. They are also on the hunt for game-changing inventive solutions to new technologies that will make thefinancial industry smarter, safer, and more environmentally responsible, as well as more user-friendly. They also function as an evergreen fund, giving them the flexibility and staying strength to focus on long-term wealth development depending on what is best for the firm and its shareholders.

Bonit Capital is a Swedish family-owned investment company. We invest across sectors and asset classes, including social investments and outcome models.Venture Capital - We invest in ambitious founders within the life science sector. We take an active ownership approach by providing capital, industry expertise and access to an internationalnetwork. Our focus areas are digital health, medical technology and diagnostics.Private Equity - We invest in entrepreneurial teams with deep sector expertise and unique market access, primarily in the lower to mid-market buyout segment, with the aim to produce superior returns and meaningful portfolio diversification.Listed Equity - Our strategy is to obtain a broad market exposure through mainly external mandates, and to seek superior returns in individual shares primarily in life science. Among Bonit's main holdings are the world-leading medtech company Elekta AB, founded by Laurent Leksell.Leksell Social Ventures - LSV is the first impact investor in Sweden with a focus on outcome models and direct investments in the areas of mental health, education and social integration. Striving for systemic change, LSV contributes to social innovation and societal development by giving social entrepreneurs and social ideas the necessary prerequisites to develop and progress – through financing, idea development and networking with private, public and nonprofit actors.

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

Hampus Jakobsson is a General Partner at early stage climate tech venture fund Pale Blue Dot.Prior to co-founding Pale Blue Dot, Hampus was a Venture Partner at science fund Blue Yard and a prolific angel investor with >100 angel investments. He co-founded of The Astonishing Tribe (acquired by Blackberry in 2010 for $150m). He left Blackberry2012 to found Brisk.io a sales productivity tool which folded 2016.

Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.

Welcome to Navigare Ventures. We invest in transformational early-stage companies at the frontier of science and technology.

We are a venture capital fund investigating in Start-Ups solving the worlds biggest problems while building massive businesses.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Crowberry Capital invests at seed and early stage in emerging technology ventures in the Nordics. Our mission is to back people that are good for companies and build companies that are good for people. We have a strong follow-through philosophy and commit to putting your company first.

GU Ventures build businesses out of groundbreaking ideas that help shape a better tomorrow. Our passionate team of company builders, financial experts, IP and legal talent ensure success for our companies.

Since 2005, Inventure has backed over 90 companies including Wolt, Swappie, Jobbatical, aiMotive, and more.

Mattias Weinhandl

Heartcore Capital invests in companies re-enchanting the world through technology.

Bonnier Capital is the investment division of the Bonnier Group. Since 2016, we invest in promising companies in structurally growing industries and have become a reliant investment partner to companies of various sizes.

European early-stage venture capital fund backed 100% by founders. Helping Pre-Seed and Seed SaaS, Marketplaces & Platforms with their Go-To-Market.

Per Båtelson

Cristina Stenbeck has been the lead shareholder of Kinnevik over the last 20 years. Cristina began her career within the Kinnevik group when she joined her first public portfolio company board in 1997. She became Deputy Chairman of Kinnevik in 2003. Served as Chairman and Executive Chairman of the Board between 2007 and 2016 and still serves on theBoard today. Kinnevik is a family-led entrepreneurial group focused on building digital consumer businesses spanning 80 countries around the world. The six investment focus areas are: Communication, e-Commerce & Marketplaces, Entertainment and Financial Services and it recently added health and education to its current consumer focus. Last year, Kinnevik made its first investment into a digital heath platform called babylon which uses advanced AI to diagnose and treat consumers' medical concerns. Kinnevik's largest investment is its 32% ownership in Zalando, Europe's leading fashion and e-commerce company. Cristina graduated with a B.Sc. from Georgetown University in Washington DC, USA and lives in Stockholm, Sweden with her family and four children.

VNV Global is an investment company with the business concept of using experience, expertise and a widespread network to identify and invest in assets with considerable potential for value appreciation. The company has a special focus on online marketplaces and businesses with strong network effects. The common shares of VNV Global are listed onNasdaq Stockholm, Mid Cap segment, with the ticker VNV.

Erik Byrenius is a founding partner of Mudcake, a microfund run by ex-founders dedicated to making the world a better place for the next generation. We invest in the strongest founders shaping the way we produce, distribute and consume food. Our typical ticket is $200k-$600k in pre-seed and seed rounds globally.Previously he was the CEO andco-founder of food delivery business OnlinePizza (exit to Delivery Hero), founder of StartupTools and co-founded the angel syndicate Nordic Makers.

We help great minds unleash their full potential!

We co-found companies, dedicating our in-house team of designers, developers, and marketers to bring ideas to life. With every venture we co-found, our mission is to advance the consumer experience across industries with world-class technology, data-informed design, and lots of heart. Are you an entrepreneur who shares our mission?

Sting – Stockholm Innovation & Growth enables talented people to turn their ideas into sustainable businesses. The support they offer includes qualified coaching in business development, a business angel network, a venture capital fund, a recruitment service, and an international network of investors, business contacts and experts. Itcontribute to the success of Sweden’s future technology companies by helping them to grow and compete internationally.

Calm/Storm is an exclusive founder network and venture capital firm. We invest in purpose driven founders changing our life & health for the better. Headquartered in Vienna, Austria we invest in early-stage companies all over Europe and the US. We focus on the pre-seed and seed stages but also invest up to Series A.

Lars-Erik Skjutare is the Chief Executive Officer at Bergendahls. Lars-Erik Skjutare attended IMD.

Josefin Landgård is the Founder and CEO of Mantle. Previously she served as the Co-Founder and COO at KRY back in March 2014 to September 2018.

Lars Lidgren is the Founder at Bonesupport.

Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion

Christer Arvidsson

Khosla Ventures invests in companies that are bold, early, and impactful. The firm was started in 2004 by Vinod Khosla, co-founder of Sun Microsystems, to provide venture assistance to entrepreneurs.Khosla Ventures invests in a range of areas including AI, climate, sustainability, enterprise, consumer, fintech, digital health, medtech anddiagnostics, therapeutics, and frontier technology.

LU Innovation is the hub for innovation and commercialisation at Lund University. They work with the University's researchers and students to bring benefit and growth to society.Their goal and mission is to contribute to increased growth in Sweden by ensuring knowledge and research from Lund University benefit society.By supporting anddeveloping research findings with researchers and students they work to lead more ideas to company formations and/or licensing deals.Services for all researchers and students:- Business advice – support and advice - Verification support – VFT- Market and IP screening – comprehensive survey of markets, competitors and patent situationThe services are freely available to researchers and students at all faculties at Lund University.An important part of the work of LU Innovation is providing commercialisation support to individual researchers or students. As well as business developers with many years of experience from both research and business, they have patent engineers, a communications officer and a lawyer who can help with the process. LU Innovation has two sections: one a part of the public authority and the other a holding company, which function as one unit with a joint mission and joint management.LU Innovation is led by the board of the holding company and the steering group of the public authority section. The members of the two bodies are identical - see board members. The operations are led by Director of Innovation Linus Wiebe, who is both MD of the holding company and head of the public authority section.

Segulah Medical Acceleration is a Scandinavia-based investment company focusing on innovative medical technology companies in Europe.

Noaber Ventures invests in initiatives that bring social transformations using information technology.

Unconventional Ventures invests in startups in the pre-seed and seed stage led by diverse founders identifying as women, people of color, immigrants and/or LGBTQ+, building scalable impact tech companies in the Nordics and beyond.

Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.

Amplifying the issues of menstruation and female sexual health and pleasure through funding and advocacy at The Case for Her.

We support early-stage founders in building global, category-defining companies. From Seed to IPO and beyond.

Laurent Leksell

Equity investment company doing Series A to late growth, private and public. Agile and long-term with no fixed holding period.

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Andreas is working on a service that will connect people, time and places on the web. He also works as an independent consultant helping other startups with product strategy, technical infrastructure, scalability and recruiting as well as financial companies (venture capital and private equity) with technical due diligence and in other advisorroles.He was CTO at Spotify from the launch of the company in August 2006 until November 2009. Before that he worked at Stardoll as an engineer and project manager.

Founder DLL-files.com - the worlds most popular website for downloading dll files Angel investor since 2008

Lambe77 adalah tempat para slotter bisa daftar dan mengakses link slot gacor dengan winrate paling paten gacor karena gampang win hanya dengan bet kecil dan merupakan bandar resmi slot88 yang dikenal sejak lama.